GSK broadens cancer portfolio via Novalent acquisition
British pharmaceutical company GSK announced a $10.6 billion acquisition deal for American Novalent, which specializes in developing cancer therapies. The deal includes three lung cancer treatments still in the trial phases, with two expected to be market-ready by the end of 2026 if they receive regulatory approvals. This move reflects the company's efforts to strengthen its presence in the oncology market and expand its portfolio of innovative medicines amid increasing global competition for promising cancer treatments.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)